CRESCENT BIOPHARMA INC (CBIO) Stock News

USA - NASDAQ:CBIO - KYG2545C1042 - Common Stock

11.35 USD

-0.92 (-7.5%)

Last: 10/10/2025, 9:14:12 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CBIO Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Crescent Biopharma

Crescent Biopharma to Present at September Investor Conferences

2 months ago - By: Crescent Biopharma

Crescent Biopharma to Present at September Investor Conferences

2 months ago - By: Benzinga - Mentions: DVN FIG GTES AMBQ

This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

2 months ago - By: Benzinga - Mentions: ALM ARM INVA

This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday

2 months ago - By: Crescent Biopharma

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

2 months ago - By: Crescent Biopharma

Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights

3 months ago - By: Crescent Biopharma

Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer

4 months ago - By: Crescent Biopharma

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

4 months ago - By: Crescent Biopharma

Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million

2 years ago - By: Catalyst Biosciences, Inc.

Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse Stock Split

2 years ago - By: Kahn Swick & Foti, LLC

CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO